US EditionNHS Makes Weight Loss Jab Guidance Change Including Wegovy and Mounjaro - 'It's Crucial'
UNITED KINGDOM, AUG 5 – NHS guidance calls for at least one year of monitoring and support after weight-loss drug treatment to prevent weight regain, affecting about 240,000 patients with greatest need.
- Health chiefs in the UK raised concerns in 2025 that patients often regain weight after stopping weight-loss drugs like Wegovy and Mounjaro.
- These concerns stem from research and reports highlighting the lack of structured advice and follow-up support after treatment ends, especially for NHS patients.
- The NHS currently provides these medications through specialist clinics to a limited number of patients, while most people pay privately and do not receive NHS aftercare.
- Nice's new quality standard mandates at least a year of monitoring and extra support after treatment, emphasizing long-term lifestyle changes and continuity of care.
- This approach aims to help patients sustain weight management success over time, recognizing weight loss as a long-term journey requiring ongoing support.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
Coverage Details
Total News Sources17
Leaning Left5Leaning Right2Center4Last UpdatedBias Distribution45% Left
Bias Distribution
- 45% of the sources lean Left
45% Left
L 45%
C 36%
R 18%
Factuality
To view factuality data please Upgrade to Premium
